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Objectives: Copious literature shows that in lung cancer many serum markers, espe-
cially the cytokeratin degradation products, correlate with the extent of disease. In
1995, we suggested the possibility of predicting the resectability of non–small cell
lung cancer by measuring the plasma level of the tissue polypeptide antigen, a
marker of the cytokeratin family. This study was designed (1) to confirm the earlier
data in a new prospective evaluation, (2) to comparatively assess another classic
biomarker (ie, the carcinoembryonic antigen), and (3) to incorporate their results
into the preoperative evaluation of non–small cell lung cancer.
Methods: We analyzed the database of a single institution over a 5-year period
(1994-1998) in a community-based hospital and second referral level institution for
a province of 500,000 people. The database included 124 consecutive patients (105
men) with pathologically documented lung cancer (50% with adenocarcinoma)
accurately staged, clinically judged operable or potentially operable, and eventually
operated on. Anthropometric, clinical, and laboratory data (including the carci-
noembryonic antigen and tissue polypeptide antigen serum levels) and the results of
a complex staging workup were prospectively recorded. Receiver-operating charac-
teristic curves and diagnostic formulas were used for data analysis.
Results: Computed tomography of the thorax, upper part of the abdomen, and brain
was the most accurate preoperative method to assess tumor resectability (receiver-
operating characteristic area: 0.76, 95% confidence intervals: 0.67-0.86, P = .000;
accuracy rate: 77%, confidence intervals: 69%-84%). Tissue polypeptide antigen
was also predictive for tumor resectability (receiver-operating characteristic area:
0.62, 95% confidence intervals: 0.51-0.73, P = .035; accuracy rate at a threshold
level of 110 U/L: 65%, 95% confidence intervals: 56%-73%). Carcinoembryonic
antigen was diagnostic only at the extreme values of its distribution (accuracy rate
at a level up to 10 ng/mL: 69%, 95% confidence intervals: 60%-77%). The proba-
bility of finding resectable disease at the time of the operation increased from 78%
(baseline computed tomography–based probability) to 83% when the concentration
of tissue polypeptide antigen was lower than 90 U/L and to 85% when the concen-
tration of carcinoembryonic antigen was below 10 ng/mL. The probability of dis-
covering an advanced disease increased from 68% (baseline computed
tomography–based probability) to 89% when tissue polypeptide antigen levels were
abnormal and to 100% when carcinoembryonic antigen concentrations were higher
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Serum tumor markers are of significance not onlyto the researcher in developing theories con-cerning tumor biology, but also to the clinicianin treating patients with cancer.1 In oncologypractice, serum tumor markers may be helpfulin the diagnosis, pathologic classifications, and
evaluation of stage of disease and prognosis. When mea-
sured serially after a diagnosis is established, they may aid
in assessing the response to treatment, monitoring the spon-
taneous course of the illness, and surveilling for tumor
recurrences.2
Lung cancer is no exception to this rule, and the expres-
sion of serum biomarkers in this particular tumor is variable
and abundant.3 Lung tumor markers fall into several cate-
gories, including oncofetal proteins, structural proteins,
enzymes, cell membrane components, secreted peptides,
hormones, and other tumor-associated antigens.3 In non–
small cell lung cancer (NSCLC), cytokeratin-derived mole-
cules and the carcinoembryonic antigen (CEA) are probably
the most helpful markers and certainly the most frequently
used.3-5
In 1995, we suggested that it should be possible to pre-
dict the resectability of NSCLC by simply measuring the
plasma level of tissue polypeptide antigen (TPA), the oldest
marker of the cytokeratin family. We were aware that such
evidence was preliminary and needed confirmation.
However, the possible equivalence of a blind serum test to
the more complex, time-consuming, and expensive multior-
gan computed tomography (CT) was a truly exciting per-
spective. Given the importance of the issue, we decided to
continue the preoperative biomarker testing in a new confir-
matory study. 
In this report, we describe the most recent experience of
the Cuneo Lung Cancer Study Group (CuLCaSG) with
CEA and TPA obtained in subjects with potentially
resectable NSCLC. As already mentioned, this study was
done mainly to confirm our earlier data. Secondary aims
were (1) the comparative assessment of TPA and the “clas-
sic” CEA and (2) the incorporation of marker test results
into the conventional preoperative evaluation of NSCLC. 
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Patients and Methods
Database and Study Design
In the fall of 1982, a group of chest physicians decided to devote
their professional activity to the study of lung cancer. The group,
which later became known as CuLCaSG, is still active at the
Department of Pulmonary Medicine of the “A. Carle” Hospital in
the city of Cuneo, Piedmont, Italy. The former “A. Carle” Hospital
for Chest Diseases merged with the “S. Croce” General Hospital,
and the two hospitals, now named “S. Croce e Carle,” were then
designated as Hospitals of National Importance. They serve the
whole Cuneo Province as a second referral institution. Among the
first acts of the CuLCaSG was the creation of a clinical database
for patients with carcinoma of the lung, effective in January 1983.
All patients with lung cancer referred to a physician of the group
were managed uniformly. Data regarding 44 variables were col-
lected for each new patient with a cytologically or pathologically
documented diagnosis of lung cancer6 and recorded on a com-
puter. This database included anthropometric and clinical charac-
teristics, routine laboratory tests and serum tumor markers, TNM
descriptors, and a computer-derived stage of disease. Since 1983,
TNM definitions have changed, radically in 1986 and minimally in
1997, because of two consecutive revisions to the International
Staging System for Lung Cancer.7,8 Therefore, to allow for homo-
geneous comparisons, we had to review the patients’ charts and
upgrade their TNM variables. This work was done as soon as the
revision of the International Staging System for Lung Cancer was
formalized. Every 4 to 5 years, the structure of the database was
modified and upgraded to new software, and the number of vari-
ables progressively increased to hundreds. However, the core vari-
ables of the early database remained unchanged, allowing for
careful analyses and time-related comparisons. In particular, of
1296 new patients with lung cancer seen consecutively during the
years 1983 to 1998, 1136 underwent a pretreatment CEA test and
1115 had a pretreatment TPA test. A large part of this population
has been the object of a number of prior publications concerning
mainly TPA.9-13 Updated descriptive statistics of the entire popu-
lation were obtained during the preparation of this article. This
update confirmed prior data, showing that both CEA and TPA lev-
els increased significantly (CEA Rs = 0.161, P = .000; TPA Rs =
0.322, P = .000), paralleling the stage of disease.8 In the entire
sample of the 1115 patients tested, median values of TPA were 70,
120, 70, 115, 114, 130, and 180 U/L, respectively, for the stages
Ia, Ib, IIa, IIb, IIIa, IIIb, and IV. Corresponding median values for
than 10 ng/mL. Conversely, the predictability of computed tomography was dimin-
ished by contrasting biomarker results, requiring further clinical investigations.
Conclusions:  Computed tomography remains the gold standard for the preoperative
evaluation of non–small cell lung cancer, although it may significantly underesti-
mate the real tumor extension. The addition of the easy and inexpensive tissue
polypeptide antigen test (with or without carcinoembryonic antigen) is capable of
correcting this underestimation and helps to decide whether to completely rely on
computed tomography or order additional clinical investigations. 
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CEA were 2 ng/mL for stages Ia to IIa and 3 ng/mL for more
advanced stages. 
All patients seen in 1994 and afterward were eligible for this
study if they had a pathologic diagnosis of NSCLC6 and had
undergone each of the following: (1) complete and accurate eval-
uation of disease extent that had indicated an almost certain or
likely tumor resectability, (2) pretreatment CEA and TPA serum
tests, and (3) thoracotomy with curative intent, which had resulted
at least in an accurate mediastinal exploration and pathologic con-
firmation of the T and N status. 
Anthropometric and clinical characteristics of the 124 assess-
able patients are shown in Table 1. 
CEA and TPA Assays
Sera for CEA and TPA were stored at –20°C, a temperature that sat-
isfactorily ensures the stability of blood specimens, and were
assayed 3 times a week in the central laboratory of the “S. Croce e
Carle” Hospital. The laboratory is located in the “S. Croce” Hospital.
It receives blood samples from many medical and surgical wards,
including the lung division at the “A. Carle” Hospital. Because we
provide no clinical information, biologists have no means of know-
ing even the disease for which a particular test is required.
Plasma measurements were performed with commercially
available radioimmunoassays (CEA test; CIS Bio International,
Gif-sur-Yvette, France; Prolifigen R, TPA IRMA; AB Sangtec
Medical, Bromma, Sweden), following the manufacturers’ instruc-
tions. Normal reference values for CEA and TPA were up to 5
ng/mL and 90 U/L, respectively. 
CT: Technique and Reading
All patients included in this report were studied with a CT scan of
the thorax, upper part of the abdomen, and brain. Up to October
1998, CT scans were performed on a conventional scanner (GE
9800; General Electric, Milwaukee, Wis); since then, a spiral-CT
machine (CT twin flash; Elscint Ltd, Haifa, Israel) has been used.
Sections of the brain, 10-mm thick, were obtained at 1-cm inter-
vals during suspended inspiration, as well as sections from the
lung apices to the upper part of the abdomen. In selected cases, 5-
mm thick sections at 5-mm intervals were acquired through the
region of interest. Iodinated intravenous contrast material (150-c3
bolus, plus 100-c3 in slow infusion) was injected before all stud-
ies. Appropriate windows were used for viewing both the lungs
and soft tissues.
Mediastinal nodes were labeled as abnormal if they were 1.5
cm or larger (transverse diameter). All CT scans were interpreted
with no restriction to the clinical information available at the time
of the examination.
Other Staging Procedures 
Other diagnostic and staging techniques did not vary considerably
during the 5 years of recorded data; furthermore, the frequent
coexistence of experimental protocols, aimed to optimize diagnos-
tic and staging procedures, ensured an overall accurate clinical
assessment. All patients received a technetium 99m methylene
diphosphonate bone scan of the entire body. In addition to this, the
baseline clinical evaluation also included a physical examination,
routine laboratory tests, bronchoscopy, and functional respiratory
tests. In half of the sample, the baseline workup was supplemented
by nonroutine imaging studies, such as the anti-CEA monoclonal
antibody scintigraphy.14 Other imaging tests, including radio-
grams, CT scans, and magnetic resonance imaging of the bones,
ultrasonographic studies of the abdomen, and other organ-specific
investigations were optional and performed as clinically indicated.
Any information obtained in this way was considered part of the
final clinical evaluation. The preoperative staging evaluation was
particularly reliable in 12 patients (10% of the cohort), who had a
pathologic stage assessment made by mediastinoscopy (11 sub-
jects) or CT-guided biopsy of a suspected (and unconfirmed) bone
TABLE 1. Anthropometric and clinical characteristics of the study population
Characteristic Median Range Frequency Percent frequency
Sex (male/female) 105/19 84.7/15.3
Age (y) 64 38-77
Weight loss (no/yes)* 79/45 63.7/36.3
ECOG performance status (0/1/2) 35/73/16 28.2/58.9/12.9
CEA serum levels (ng/mL), No. abnormal 2 0-60 21 16.9
TPA serum levels (U/L), No. abnormal 80 30-790 49 39.5
Tumor cell type (A/S/L/M) 62/49/11/2 50/39.5/8.9/1.6
Pathologic stage of disease (Ia/Ib/IIa/IIb/IIIa/IIIb/IV)† 28/42/5/13/18/15/3 22.6/33.9/4/10.5/14.5/12.1/2.4
T factor (1/2/3/4) 35/59/14/16 28.2/47.6/11.3/12.9
N factor (0/1/2) 8/22/20 66.1/17.7/16.1
M factor (0/1) 120/4 96.8/3.2
Type of operation (ET/SE/LO/BI/PN) 20/5/69/6/24 16.1/4/55.6/4.8/19.4
Postoperative follow-up time (mo) 19.2 1-64
Status 64/60 51.6/48.4
ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; TPA, tissue polypeptide antigen; A, adenocarcinoma; S, squamous cell car-
cinoma; L, larger cell carcinoma; M, mixed histologic type; ET, exploratory thoracotomy; SE, segmentectomy; LO, lobectomy; BI, bilobectomy; PN, pneu-
monectomy.
*In the 6 months preceding the operation.
†1997 Stage classification.
894 The Journal of Thoracic and Cardiovascular Surgery • November 2001
ED
ITO
RIA
L
CH
D
G
TS
A
CD
ET
CSP
TX
metastasis (1 subject). Because we considered both anti-CEA
immunoscintigraphy and the marker assay to be investigative, no
clinical decision was made on the sole basis of their results. 
All staging tests were obtained within a 3- to 4-week period
and no thoracotomy was performed later than 30 days after the
first physical examination.
Data Analysis and Statistical Considerations
Diagnostic capabilities were calculated for the final clinical
assessment, CT reading, CEA, TPA, and CEA-TPA combined
variable (mean of the two marker values expressed in percentage
of their reference of 5 ng/mL [CEA] and 90 U/L [TPA]). For CEA,
TPA, and CEA-TPA, one or multiple threshold levels were chosen
to describe a positive or negative test result. In this study, diagnos-
tic capabilities are not intended to show the presence or absence of
disease, but the presence (or absence) of the condition of full
resectability, that is, the pathologic postoperative documentation
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of stage Ia through IIb disease. Accordingly, a marker level below
a given threshold or a CT result suggestive of stage Ia-IIb was
declared true positive when the actual pathologic stage was Ia to
IIb and false positive when the latter was IIIa or more. Markers
over the considered threshold or more advanced CT stages were
considered true negative or false negative when the corresponding
pathologic stage was, respectively, IIIa-IV or Ia-IIb. 
Statistical analysis was performed with the use of the SPSS
package for Windows, version 9.0 (SPSS, Inc, Chicago, Ill).
Continuous variables were described by medians and ranges
because in many instances, such as in the case of CEA and TPA,
their distribution was not gaussian.15 Sensitivity, specificity, and
accuracy, along with predictive positive and negative values, were
obtained by means of standard diagnostic formulas.16 Diagnostic
proportions were given along with their 95% confidence intervals
(CI).17 To compare diagnostic capabilities, we used the receiver-
operating characteristic curves,18 whose circumscribed areas (the
TABLE 2. Cross-tabulation between major preoperative estimates and pathologic findings
1997 Pathologic stage
Ia Ib IIa IIb IIIa IIIb IV Total
1997 CT stage
Ia 21 9 1 3 1 35
Ib 5 25 2 6 4 4 46
IIa 1 2 1 4
IIb 4 2 3 4 6 1 20
IIIa 1 3 7 3 14
IIIb 1 1 2
IV 1 2 3
Total 28 42 5 13 18 15 3 124
Final clinical evaluation*
69 10
Yes 24 34 5 6 5 5 79
No 4 8 0 7 13 10 3 45
19 26
*Based on medical history, physical examination, bronchoscopy, 3-organ CT scanning, and any other preoperative available investigation.
TABLE 3. Tumor resectability*: ROC analysis
All patients (n = 124) AUC 95% CI P value
CT† 0.763 0.666-0.861 .000
TPA (U/L) 0.621 0.511-0.732 .035 (Figure 1, A)
Average of CEA and TPA‡ 0.616 0.507-0.725 .043
CEA (ng/mL) 0.573 0.467-0.680 .201 (Figure 1, B)
AUC, Area under the curve; ROC, receiver-operating characteristic; CI, confidence interval; CT, computed tomography; TPA, tissue polypeptide antigen;
CEA, carcinoembryonic antigen.
*Diagnosis of postoperative stage Ia-IIb (pathologically confirmed).
†CT of the thorax, upper part of the abdomen, and brain.
‡Values of TPA and CEA are expressed as a percent of their reference values (90 U/L and 5 ng/mL, respectively), added up, and divided by 2.
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area under the curve) give an estimate of the diagnostic effi-
ciency.19 Correlations and differences were tested for statistical
significance by means of the Spearman rank test and the Kruskal-
Wallis analysis of variance.15 All statistical tests were 2-sided.
Results
Descriptive Statistics
Table 1 shows the anthropometric and clinical characteristics
of the patient population, with descriptive statistics on sex,
age, history of weight loss, performance status (Eastern
Oncology Group scale20), and CEA and TPA serum levels.
Also reported are tumor cell type, the postoperative patho-
logic stage of disease, the correlated parameters of disease
extension, the type of surgical treatment, the survival dura-
tion, and the patients’ status at the last follow-up reassess-
ment. As of May 1999, 64 of 124 patients (52%) were still
alive after a median follow-up of 19 months (range 1-64
months). Most recruited patients had an early stage of disease
and had favorable surgical outcomes. A total of 88 patients
had completely operable disease (postoperative stages Ia, Ib,
IIa, or IIb), another 18 subjects might have benefited from the
Figure 1. Receiver-operating characteristic curves showing the predictive capability of TPA (A) and CEA (B). The
preoperative diagnosis was postoperative pathologic stage Ia-IIb.
Figure 2. Receiver-operating characteristic curves showing the predictive capability of TPA for the T factor (A)
and the N factor (B). The preoperative diagnosis was postoperative pathologic factors T1-2 N0-1.
A B
A B
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operation (stage IIIa), and 18 others had a nonoperative con-
dition (stage IIIb or IV). This resulted in 104 pulmonary
resections and 20 exploratory thoracotomies. 
Median values (ranges) of CEA and TPA in the postop-
erative pathologic stage Ia-IIb were, respectively, 2 ng/mL
(0-60 ng/mL) and 70 U/L (30-360 U/L). Corresponding val-
ues for postoperative stages IIIa-IV were 2.5 ng/mL (1-22
ng/mL) and 100 U/L (40-790 U/L). The correlation between
serum levels of TPA and the pathologic stage of disease was
statistically significant (Spearman R = 0.3, P = .001),
whereas that of CEA did not reach the significance level (Rs
= 0.162, P = .072). No significant difference in the distribu-
tion of the serum markers’ concentration among different
histotypes was observed (Kruskal-Wallis statistic). 
Diagnosis of Postoperative Pathologic Stage by Means
of a 3-Organ CT and the Best Clinical Assessment 
Table 2 shows a cross-tabulation between the 3-organ CT
stage and the best clinical assessment on the one hand and
the postoperative pathologic stage on the other. On the basis
of CT, the preoperative classification was stage Ia-IIb in 105
patients. Stage Ia-IIb disease was confirmed postoperatively
in only 88 of them. By contrast, there were 19 patients with
CT-diagnosed stage IIIa-IV disease and 36 patients with
truly inoperable disease. This means a considerable CT
underestimation of the real extent of disease, partially cor-
rected by the completion of the full staging workup. The
final and best clinical assessment, however, showed no
General Thoracic Surgery Buccheri and Ferrigno
greater diagnostic accuracy, because of an increased over-
estimation of the real disease (Table 2). 
Diagnosis of Resectable Disease (Postoperative
Pathologic Stage Ia-IIb), 3-Organ CT Findings, and
CEA and TPA Serum Levels
TPA and CEA differed remarkably in their capability to dis-
close early stages of disease. In particular, the diagnosis of
postoperative stage Ia-IIb was only partially correct with
TPA and inaccurate with CEA (Figure 1). The area under
the receiver-operating characteristic curve was 0.621 (P =
.035) for TPA and 0.57 (P = .201) for CEA (Table 3). Three-
organ CT was the most accurate method for the preopera-
tive diagnosis of resectability (Table 4). For a TPA of 90
U/L or less, the diagnostic sensitivity was 67%, and the
specificity and accuracy rates were, respectively, 56% and
64% (Table 4). A normal level of TPA was properly associ-
ated with resectable disease in 79% of the patients (95% CI:
69%-88%), and a higher level was diagnostic of advanced
disease in 41% (95% CI: 27%-55%). TPA was also capable
of diagnosing resectability when the T or the N factors
alone were taken into consideration (Figure 2). For a CEA
level up to 5 ng/mL, sensitivity, specificity, and accuracy
rates were, respectively, 82%, 14%, and 62%, whereas the
probability of properly diagnosing a condition of resectabil-
ity was 70% (CI: 61%-79%). The combination of CEA and
TPA (CEA-TPA combined variable) was unable to increase
the overall diagnostic accuracy of TPA alone (Table 4). 
TABLE 4. Tumor resectability*: Diagnostic formulas 
TP TN FP FN Total SE (%) SE (CI) (%)
Single test evaluations:
CT† 82 13 23 6 124 93 88-98
Final clinical evaluation‡ 69 26 10 19 124 78 70-87
TPA (up to 80 U/L, median) 50 21 15 38 124 57 46-67
TPA (up to 90 U/L, RF) 59 20 16 29 124 67 57-77
TPA (up to 110 U/L) 67 13 23 21 124 76 67-85
CEA (up to 2 ng/mL, median) 58 18 18 30 124 66 56-76
CEA (up to 5 ng/mL, RF) 72 5 31 16 124 82 74-90
CEA (up to 10 ng/mL) 81 4 32 7 124 92 86-98
Average of CEA and TPA§ 61 16 20 27 124 69 60-79
CT evaluations stratified by:
TPA (≤90) 54 5 11 5 75 92 84-99
TPA (>90) 28 8 12 1 49 97 90-103
CEA (≤10) 75 12 20 6 113 93 87-98
CEA (>10) 7 1 3 0 11 100 100-100
TP, True positive; TN, true negative; FP, false positive; FN, false negative; SE, sensitivity; SP, specificity; AC, accuracy; PPV, positive predictive value;
NPV, negative predictive value; CI, 95% confidence interval; CT, computed tomography; TPA, tissue polypeptide antigen; CEA, carcinoembryonic antigen;
RF, reference value; NC, noncalculable.
*Diagnosis of postoperative stage Ia-IIb, confirmed pathologically.
†CT of the thorax, upper part of the abdomen, and brain.
‡Based on the results of physical examination, routine laboratory tests, bronchoscopy, 3-organ CT, and any other preoperative available investigation.
§Values of TPA and CEA are expressed in percent of their reference values (90 U/L and 5 ng/mL, respectively), added up, and divided by 2.
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Stratifying the CT-based stage of disease by marker
results (Table 4) identified two different situations. The first
was the presence of concordant findings (which increased
both positive and negative predictive values of CT); the sec-
ond was the occurrence of bidirectional discordant data (this
lowered CT predictability). The TPA-stratified CT stage
was the best possible combination of CT and any one single
marker (Table 4). As shown, the presence of a normal TPA
level increased the chance, based on CT, of correctly pre-
dicting tumor resectability from 78% (CI: 70%-86%) to
83% (CI: 74%-92%). The opposite situation was associated
to a diagnostic improvement of 21%, from the 68% rate of
negative predictability of a sole CT suggesting nonre-
sectability (CI: 48%-89%) to 89% (CI: 68%-109%). In the
area of uncertainty of an abnormal TPA and tumor
resectability suggested by CT (or vice versa, conversely, of
normal TPA and presence of advanced disease on CT), the
CT diagnosis of resectable disease was correct in about 50%
to 70% of the cases (Table 4). 
Discussion
This study aimed to assess, in resectable NSCLC, the exact
diagnostic capability of two serum biomarkers, CEA and
TPA, that are commonly measured in many European
countries21 but are still ignored by important medical soci-
eties.22,23
CEA is an oncofetal protein found normally in the
embryonic and fetal gut, produced sometimes by malignant
cells. It was discovered in 1965 by Gold and Freedman24 in
the sera of subjects with adenocarcinoma of the colon.
Raised CEA concentrations may be detected in persons who
smoke, in patients with benign tumors, and in 15% to 20%
of subjects with inflammatory disorders such as ulcerative
colitis, pancreatitis, liver disease, and pulmonary infec-
tions.25 Abnormally elevated concentrations of CEA can be
found in 30% to 70% of patients with lung cancer.11,13,26-28
Raised levels of CEA are particularly common in those with
adenocarcinoma28,29; however, they can be present in any
histologic type.26,27 Studies have shown that increased con-
centrations of CEA occur more frequently in advanced can-
cers,12,27 although reported differences are not always
statistically significant.11
Nearly half a century ago, Björklund30 discovered a new
antigen by mixing many different tumors and producing an
immune serum against the mixture. He called it TPA. TPA
has been subsequently identified as a degradation product
of the cytoskeleton, formed by the cytokeratins 8, 18, and
19.31 The cytoskeleton is a complex network that influ-
ences the dynamic structure of all eukaryotic cells in their
tissue environment.32 It is composed of microfilaments (7-
9.5 nm in diameter), microtubules (25 nm), and intermedi-
ate filaments (10-12 nm).32 Cytokeratins are the major
components of the intermediate filaments.33 Cytokeratins
may be divided into 20 different types, according to mole-
cular weight and isoelectric point.34 The expression of a
single cytokeratin or a combination of certain cytokeratins
is typical of a specific tissue. Elevated serum concentra-
tions of TPA (ie, of cytokeratins 8, 18, and 19) have been
observed in different types of epithelial cancers.35 In lung
cancer, pretreatment levels of TPA are often elevated, par-
ticularly in the later stages of disease.9-13,36-38
As already mentioned, this is not our first attempt to
define a clinical strategy capable of exploiting the widely
known correlation between tumor burden and serum marker
concentration. In 1995, in this Journal, we36 reported a study
specifically designed to investigate the use of TPA as a com-
mon test of preoperative assessment. We considered 104
patients with NSCLC who had undergone thoracotomy,
SP (%) SP (CI) (%) AC (%) AC (CI) (%) PPV (%) PPV (CI) (%) NPV (%) NPV (CI) (%)
36 20-52 77 69-84 78 70-86 68 48-89
72 58-87 77 69-84 87 80-95 58 43-72
58 42-74 57 49-66 77 67-87 36 23-48
56 39-72 64 55-72 79 69-88 41 27-55
36 20-52 65 56-73 74 65-83 38 22-55
50 34-66 61 53-70 76 67-86 38 24-51
14 3-25 62 54-71 70 61-79 24 6-42
11 1-21 69 60-77 72 63-80 36 8-65
44 28-61 62 54-71 75 66-85 37 23-52
31 9-54 79 69-88 83 74-92 50 19-81
40 19-61 73 61-86 70 56-84 89 68-109
38 21-54 77 69-85 79 71-87 67 45-88
25 –17-67 73 46-99 70 42-98 100 100-100
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mediastinoscopy, or biopsy of suspected metastatic deposits
in addition to an extensive noninvasive evaluation of the stage
of disease. We made several retrospective evaluations, but the
two most pertinent to this study were those regarding TPA
and the readings of a CT of the brain, thorax, and upper por-
tion of the abdomen. Among the 20 threshold values consid-
ered, ranging from 45 U/L to 450 U/L, we identified two
thresholds for detecting the postoperative stage of disease
with the highest rate of success. Then, on the basis of the
pathologic reference, we determined the sensitivity, speci-
ficity, accuracy, and predictive capabilities of both CT and
TPA at the thresholds of 110 U/L and 160 U/L. We found that
CT and TPA had a diagnostic accuracy of, respectively, 79%
and 68% for stages I and II; 69% and 77% for stage IIIa; and
77% and 76% for stages IIIb and IV (1987 International
Union Against Cancer [UICC] classification). Impressed by
those results, we postulated the equivalence of TPA and CT
in predicting surgical resectability. This study starts from that
premise, but it limits the focus to what we think is the most
clinically important information. Is the patient under assess-
ment a surgical candidate or does he or she have a condition
that is partially or completely inoperable? We can summarize
our current findings as follows:
1. The preoperative assessment of tumor resectability,
based on a CT scan of brain, thorax, and upper part of the
abdomen, is acceptably accurate (accuracy rate: 77%). 
2. The 20% to 25% margin of error is not appreciably
reduced by the addition of any other preoperative investigation.
3. In patients considered for surgery, a blind single
serum test of TPA is diagnostic of full resectability (postop-
erative stage Ia-IIb) at an overall accuracy rate of 65%. 
4. Very elevated levels of CEA (above 10 ng/mL) are
also capable of recognizing a postoperative resectable dis-
ease (accuracy rate: 69%). 
5. The stratification of CT readings by TPA (serum test
results up to 90 U/L or more) allowed us to identify a group
of 9 patients, among the 19 with supposedly inoperable dis-
ease, who had a particularly high risk of unresectable dis-
ease (89%) and another 65, among the 105 judged operable,
whose tumors were more often resectable (83%). The
remaining 50 subjects were left in an area of uncertainty that
required further clinical testing. 
6. In slightly smaller groups, the stratification of CT data
by both CEA (cutoff: 10 ng/mL) and TPA (cutoff: 90 U/L)
made it possible to accurately discriminate between
resectability and nonresectability, increasing the negative
predictive efficiency to 85% to 100%. 
Conclusions
Evidence from this study suggests obtaining a routine TPA
test (and possibly a CEA test) in all patients with potentially
operable NSCLC. CT remains the gold standard for the pre-
operative evaluation of NSCLC. However, it may signifi-
cantly underestimate the real extension of tumor. The TPA
test is capable of correcting such an underestimation and
helps to determine the next steps. We believe that a 3-organ
CT showing a resectable tumor (stage Ia-IIb) and a TPA
level up to 90 U/L in an asymptomatic subject are clear indi-
cations for immediate operation. On the other hand, a higher
TPA value (or a very high level of CEA) associated with CT
findings of nonresectability (stage IIIa-IV) virtually elimi-
nates any surgical approach. In case of conflicting data, the
patient is still a surgical candidate, but an intensification of
the preoperative evaluation is mandatory. This could be
obtained by ordering a bone scan or performing a medi-
astinoscopy, even in the absence of symptoms and signs. 
We thank Lorena Gribaudo and Anna Merlo, nurses of the out-
patient unit, for their help and support.
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